EFFECTIVENESS AND COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR AND BOCEPREVIR FOR CHRONIC HEPATITIS C: A DECISION ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM

被引：0
作者：
Borba, H. H. [1 ]
Rochau, U. [2 ]
Wiens, A. [1 ]
Sroczynski, G. [2 ]
Siebert, U. [3 ]
Pontarolo, R. [1 ]
机构：
[1] Univ Fed Parana, Curitiba, Parana, Brazil
[2] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & HTA, Dept Publ Hlth Hlth Serv Res & HTA, Hall In Tirol, Austria
[3] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Hall In Tirol, Austria
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2627
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI9
引用
收藏
页码：A883 / A883
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF BOCEPREVIR-BASED TREATMENT OF CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
    Becker, B.
    Chhatwal, J.
    Ferrante, S.
    Elbasha, E. H.
    Krobot, K. J.
    VALUE IN HEALTH, 2012, 15 (07) : A392 - A392
  • [42] Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system
    Bahia, Luciana Ribeiro
    Araujo, Denizar Vianna
    Pepe, Camila
    Trindade, Michelle
    Camargo, Caroline Mendonca
    Javaroni, Valter
    INTERNATIONAL BRAZ J UROL, 2012, 38 (05): : 595 - 605
  • [43] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER 'REAL-LIFE' CONDITIONS
    Ruiz-Antoran, B.
    Sancho-Lopez, A.
    Payares, C.
    de la Revilla, J.
    Calleja Panero, J. L.
    Avendano-Sola, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 18 - 18
  • [44] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    Gea, F.
    Barcena, R.
    Larrubia, J.
    Perez Alvarez, R.
    Sousa, J.
    Romero-Gomez, Manuel
    Sola, R.
    de la Revilla, J.
    Crespo, J.
    Navarro, J.
    Arenas, J.
    Delgado, M.
    Fernandez Rodriguez, C.
    Planas, R.
    Buti, M.
    Forns, X.
    Calleja, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A367 - A367
  • [45] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Jacobs, RJ
    Koff, RS
    HEPATOLOGY, 2000, 32 (04) : 873 - 874
  • [46] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Myers, RP
    Gregor, JC
    Marotta, PJ
    GASTROENTEROLOGY, 1999, 116 (04) : A1252 - A1252
  • [47] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    de la Revilla, J.
    Crespo, J.
    Salcedo de Diego, I.
    Payares, C.
    Forns, X.
    Calleja, J. L.
    Avendano-Sola, C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E154 - E154
  • [48] Cost-effectiveness analysis of pharmaceutical care for hypertensive patients from the perspective of the public health system in Brazil
    Cazarim, Maurilio de Souza
    Leira Pereira, Leonardo Regis
    PLOS ONE, 2018, 13 (03):
  • [49] Cost-effectiveness of saxaglipitin in the Brazilian supplementary health system
    de Oliveira, Italo Martins
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2013, 59 (02): : 101 - 101
  • [50] Cost-effectiveness analysis - a health policy perspective
    Maini, BS
    SURGERY, 1999, 126 (05) : 989 - 989
12345